Literature DB >> 23839658

Pharmacological management of depression in patients with cancer: practical considerations.

Riccardo G V Torta1, Valentina Ieraci.   

Abstract

This article provides an overview of the prevalence, pathogenesis and diagnosis of, and treatment strategies for, depression in cancer patients. Untreated depression can increase the burden of oncology symptoms and worsen the cancer prognosis through the relationship between mood and immunity. The issues to consider when treating a patient with cancer who has depression include when to introduce pharmacotherapy, the criteria for choosing an antidepressant, and the necessary caution regarding side effects and drug interactions. The choice of an antidepressant is a complex decision that has to balance previous pharmacological experiences, different clusters of target symptoms, pharmacological interactions, and objective and subjective risks of side effects, with the aim of tailoring a strategy for each patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839658     DOI: 10.1007/s40265-013-0090-7

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  130 in total

1.  CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Authors:  Catherine M Kelly; Kathleen I Pritchard
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

2.  How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain.

Authors:  Amy A McDonald; Russell K Portenoy
Journal:  J Support Oncol       Date:  2006-01

3.  A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Authors:  Dominique L Musselman; Wendy I Somerset; Ying Guo; Amita K Manatunga; Maryfrances Porter; Suzanne Penna; Barbara Lewison; Rebecca Goodkin; Kathryn Lawson; David Lawson; Dwight L Evans; Charles B Nemeroff
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

4.  Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.

Authors:  Meaghan Creed-Carson; Alhan Oraha; José N Nobrega
Journal:  Behav Brain Res       Date:  2011-01-22       Impact factor: 3.332

5.  Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline.

Authors:  G Pezzella; R Moslinger-Gehmayr; A Contu
Journal:  Breast Cancer Res Treat       Date:  2001-11       Impact factor: 4.872

Review 6.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

7.  Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy.

Authors:  Derenik Gharibian; Jennifer K Polzin; Jay P Rho
Journal:  Clin J Pain       Date:  2013-05       Impact factor: 3.442

8.  Bupropion sustained release treatment reduces fatigue in cancer patients.

Authors:  Jodi L Cullum; Agnieszka E Wojciechowski; Guy Pelletier; J Steven A Simpson
Journal:  Can J Psychiatry       Date:  2004-02       Impact factor: 4.356

Review 9.  Symptom cluster: Depression and pain.

Authors:  Riccardo G V Torta; Jacopo Munari
Journal:  Surg Oncol       Date:  2010-01-27       Impact factor: 3.279

10.  Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.

Authors:  Helen Bould; Nicola Wiles; John Potokar; Philip Cowen; David J Nutt; Tim J Peters; Glyn Lewis
Journal:  J Psychopharmacol       Date:  2012-01-04       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.